Targeted Therapy for Muscle-Invasive Bladder Cancer
Targeted therapy uses drugs to target specific changes in cancer cells that help them grow, divide, and spread. Targeted therapy drugs are designed to be more precise. They fight cancer cells while causing less harm to other cells in the body.
These are the latest targeted therapies that are approved to treat muscle-invasive bladder cancer. New treatments become available all the time, so this may not be a complete list.
Please note: The side effects listed here do not represent a comprehensive list. It's important to discuss all potential side effects of a drug with your health care team. Be sure to tell your health care team about any side effects you do have.
All Available Treatments
Intravenous = 
Pill = 
Treatment Type
TKI
Drug Name
Balversa™ (erdaitinib) (Pill)
Important Things to Know
This medication can be used for patients with FGFR3 mutations.
Treatment Type
Trop-2 Directed Antibody and Topoisomerase Inhibitor Conjugate
Drug Name
Trodelvy® (sacituzumab govitecan) (IV)
Potential Side Effects
Constipation
Diarrhea
Fatigue/weakness
Hair thinning/loss
Low blood counts
Nausea/vomiting
Skin/nail changes
Weight/appetite changes
Important Things to Know
- This medication can be used for patients with PD-L1 biomarker.
- Low blood counts are a potential side effect that may put you at risk for anemia, infection, or bleeding.
Treatment Type
Monoclonal antibody
Drug Name
Padcev® (enfortumab-vedotin) (IV)
Potential Side Effects
Diarrhea
Dry eye
Fatigue/weakness
Hair thinning/loss
Low blood counts
Nausea/vomiting
Neuropathy
Skin/nail changes
Weight/appetite changes
Important Things to Know
- This medication can be used for patients with PD-L1 biomarker.
- Low blood counts are a potential side effect that may put you at risk for anemia, infection, or bleeding.